EcoDrugPlus

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSCJAG00000014274
Gene Symbol: ADRM1
4 Cross references
260 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Akt Serine/threonine Kinase 1

Ensembl ID : ENSCJAG00000009300
Gene Symbol: AKT1
5 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Akt Serine/threonine Kinase 2

Ensembl ID : ENSCJAG00000014574
Gene Symbol: AKT2
5 Cross references
257 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Akt Serine/threonine Kinase 3

Ensembl ID : ENSCJAG00000017090
Gene Symbol: AKT3
5 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSCJAG00000008763
Gene Symbol: ALK
5 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSCJAG00000005641
Gene Symbol: ABCC1
5 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSCJAG00000009368
Gene Symbol: ABCC8
5 Cross references
245 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSCJAG00000042358
Gene Symbol: ABCC9
5 Cross references
233 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSCJAG00000010270
Gene Symbol: ATP4A
3 Cross references
183 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSCJAG00000006956
Gene Symbol: ATP4B
5 Cross references
171 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSCJAG00000006058
Gene Symbol: ATP1A1
5 Cross references
328 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Alpha 2

Ensembl ID : ENSCJAG00000006022
Gene Symbol: ATP1A2
5 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).